Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
Giuseppe Buono(Federico II University Hospital), Grazia Arpino(University of Naples Federico II), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfonso Amore(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anita Minopoli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmen G. Rea(University of Naples Federico II), Meghana V. Trivedi(University of Houston), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Carmen Pacilio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Porciello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Rossella Lauria, Emanuela Esposito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Schettini(Target (United States)), Aldo Giudice(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Flavia Nocerino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 70
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724